Moderna, Inc. (MRNA) Jun 2026 Filing Analysis

The commitment is tracking positively, but the full-year outcome is not yet available. Management reaffirmed the expectation after substantial year-to-date reductions. (1 in progress across 1 tracked commitment)

mNEXSPIKE received FDA approval in May 2025 and commercial sales began in the third quarter of 2025, ahead of or in time for the 2025–2026 season. (1 met, 1 dropped across 2 tracked commitments)

Management anticipates a modest decrease in cost of sales in 2026, excluding the Arbutus/Genevant settlement impact; excluding that impact, cost of sales as a percentage of net product sales and stand-ready manufacturing revenue is expected to decrease moderately as sales increase. — target: Modest year-over-year decrease in cost of sales; moderate decrease in cost of sales as a percentage of net product sales and stand-ready manufacturing revenue, excluding settlement impact (+2 more commitments)

This revenue stream was newly visible in Q3 FY25 through government agreements requiring Moderna to maintain domestic mRNA manufacturing readiness. The company recognized $20 million of miscellaneous other revenue in the quarter, representing approximately 2.0% of total revenue. The filing does not provide a comparable Q3 FY24 amount for this specific stream, so its year-over-year growth cannot be quantified. (2 new, 1 shifted, 1 expanding)

Moderna's scale and distribution moat expanded operationally during Q3 FY25 as manufacturing facilities in Australia and the United Kingdom became licensed and operational, while the Canadian facility produced its first fully manufactured mRNA vaccines. This strengthens local supply and pandemic-readiness capabilities, but near-term economics remain pressured by unused capacity, inventory write-downs, and fixed manufacturing costs. (1 expanding)

The regulatory moat expanded through additional approvals and product filings. Moderna launched mNEXSPIKE in the U.S. in Q3 2025, expanded mRESVIA's U.S. indication to certain adults ages 18-59, and had multiple flu and combination-vaccine applications under review. This broadens the approved and review-stage product base, although approval timing remains uncertain. (1 expanding, 1 new)

Grant revenue doubled year over year, increasing from $7 million to $14 million and expanding its share of total revenue from 0.4% to 1.4%. However, the filing also indicates that the large BARDA COVID contract concluded in June 2025 and that the terminated influenza award generated immaterial revenue, so the latest increase is not clearly a durable recurring growth stream. (3 expanding, 2 contracting across 3 engines)

Net product sales expanded sharply from Q1 2025 to Q1 2026, rising 309%. They represented 90.5% of total revenue in Q1 2026, versus 79.6% in Q1 2025. The latest quarter therefore shows expansion, although the stream remains heavily dependent on COVID vaccines. (2 expanding, 3 contracting across 1 engine)

Manufacturing capacity is being expanded, but near-term utilization remains a drag. Property, plant and equipment rose from $1.945 billion to $2.381 billion, including $975 million of construction in progress. Moderna also agreed to buy its Norwood manufacturing center for approximately $370 million and obtained a Canadian drug establishment license, with production expected to begin in 2025. At the same time, Q3 included $27 million of unused-capacity and wind-down costs, showing that capacity benefits have not yet fully translated into demand or efficiency. (3 accelerating, 1 decelerating, 1 new trend across 5 signals, 5 leading indicators)

U.S. sales are accelerating: quarterly sales increased 33% year over year to $1.215 billion, while nine-month sales increased 61% to $1.477 billion. The improvement was driven by earlier FDA approval and launch of the updated COVID-19 vaccine, which allowed Moderna to meet seasonal demand more effectively. (4 accelerating, 1 reversing across 5 signals)

Cost efficiency is improving materially, especially against the prior-year inventory and capacity reset. Q3 cost of sales fell 77% year over year to $514 million, R&D fell 2% to $1.137 billion, and SG&A fell 36% to $281 million. Cost of sales declined from 128% of net product sales to 28% in Q3, while nine-month cost of sales fell from 97% to 33%. The latest quarter reached near break-even operating performance, but the improvement is partly driven by unusually large 2023 inventory write-downs and restructuring charges. (1 accelerating, 1 reversing, 1 decelerating, 2 steady across 5 signals)

The main near-term growth constraint is still uncertain COVID vaccine demand in the U.S. and the risk of excess inventory. U.S. product sales fell 20% year over year in Q2 to $70 million, while Moderna recorded $41 million of Q2 inventory write-downs and held $361 million of total vaccine inventory at June 30. — U.S. demand and vaccine inventory risk: U.S. product sales: -20% YoY; inventory write-downs: $41 million in Q2

The risk remained very high and was still worsening in the most recent reported quarter. Moderna recorded a $2.0 billion net loss and used $2.8 billion of operating cash in the first nine months of 2025. Cash, cash equivalents, and investments fell 30% from $9.519 billion at year-end 2024 to $6.647 billion at September 30, 2025. The company stated that it expected continued negative operating cash flow and warned that its runway estimate could prove wrong. Compared with the Jun 2026 baseline, the company later continued to report large losses and cash use, so the underlying risk was not resolved. (4 intensifying, 1 high-severity)

From Q3 2024 to Q3 2025, this risk intensified materially. Net product sales fell 47% year over year to $973 million, while COVID products generated $971 million, or approximately 100% of product sales. U.S. product sales declined from $1.215 billion to $782 million, and management attributed the decline to lower COVID vaccination rates and a more competitive commercial market. Moderna also stated that the decline in demand continued in 2025 and expected full-year COVID and RSV sales to decline versus 2024. Compared with the Jun 2026 baseline, the later baseline shows an even smaller COVID business, so the deterioration continued after this filing. (4 intensifying, 1 high-severity)

The earnings risk remained severe. For the first nine months of 2025, total revenue fell 44% to $1.266 billion, while operating expenses were $3.483 billion and the operating loss was $2.217 billion. Cost of sales was 35% of net product sales, up from 33% in the prior-year period, despite lower absolute cost. Research and development still consumed $2.357 billion, or nearly twice total revenue. The company reduced spending, but the revenue decline outpaced the cost reductions. The Jun 2026 baseline later showed cost of sales exceeding product sales, indicating further deterioration after this filing. (3 intensifying, 1 stable, 2 high-severity)

The risk intensified during the reported period. COVID generated $1.168 billion of $1.172 billion in nine-month product sales, or approximately 100%, while RSV generated only $4 million. Although Moderna had three commercial products and launched mNEXSPIKE, the new product is another COVID vaccine rather than a meaningful diversification away from COVID. RSV sales fell from $10 million to $4 million year over year. The pipeline remained dependent on future clinical and regulatory success; the CMV program subsequently failed its primary endpoint in October 2025 and was discontinued, further illustrating execution risk in diversification. The Jun 2026 baseline shows that RSV remained immaterial and the combination vaccine had not yet been commercialized. (3 intensifying, 2 stable, 3 high-severity)

Liquidity weakened materially during the period. Cash, cash equivalents, and investments declined by $2.872 billion, or 30%, from December 31, 2024, while operating cash use was $2.803 billion. Moderna also had $1.086 billion of future operating lease payments, $522 million of non-cancelable raw-material and manufacturing commitments, and $1.2 billion of non-cancelable research and development and other commitments. The company said funding was sufficient for at least 12 months, but explicitly noted that actual cash use could be faster than forecast. The Jun 2026 baseline later showed a further liquidity decline and a large patent settlement, confirming that the risk intensified after this filing. (4 intensifying, 1 high-severity)